Salim Syed
Stock Analyst at Mizuho
(2.18)
# 2,756
Out of 4,944 analysts
75
Total ratings
41.67%
Success rate
-2.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.23 | +529.21% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $37.04 | +126.78% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $135.10 | +25.09% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $289.49 | -3.28% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $120.12 | -2.60% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $8.77 | +150.86% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $31.63 | +415.33% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $12.14 | +48.27% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $19.81 | +71.63% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $59.21 | +67.20% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $50.45 | +5.05% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.00 | +2,005.47% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $24.69 | +45.84% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.23
Upside: +529.21%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $37.04
Upside: +126.78%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $135.10
Upside: +25.09%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $289.49
Upside: -3.28%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $120.12
Upside: -2.60%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $8.77
Upside: +150.86%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $31.63
Upside: +415.33%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $12.14
Upside: +48.27%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $19.81
Upside: +71.63%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $59.21
Upside: +67.20%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $50.45
Upside: +5.05%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.00
Upside: +2,005.47%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $24.69
Upside: +45.84%